Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a relatively new class of drugs revolutionizing the treatment of T2DM, so that in the latest guidelines, GLP-1RAs are even recommended as a first-line treatment for T2DM patients with cardiovascular disease, renal insufficiency, or overweight/obesity [4, 5]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.